New ADHD Drug Trial for Teens Launches and Parents Deserve the Full Story
Last updated:
If your teen struggles with focus, the medication question rarely stays simple. You balance what the prescriber recommends against what the research shows, and what most people around you assume is the only path forward. On June 26, 2026, Axsome Therapeutics announced the first patient had been dosed in FOCUS-3, a Phase 3 clinical trial testing solriamfetol as a non-stimulant ADHD treatment in 468 adolescents ages 12 to 17. The drug pipeline news is real and worth knowing. What most coverage skips is three decades of research showing that attention is a trainable cognitive skill, and that training it changes the brain in ways no six-week medication trial is designed to track.
TL;DR
Axsome Therapeutics dosed the first patient in FOCUS-3 on June 26, 2026, a Phase 3 trial of the non-stimulant solriamfetol in 468 adolescents ages 12 to 17 with ADHD.
The six-week trial measures symptom change; FDA approval, if it comes, requires full trial success and regulatory review.
CDC data shows approximately 7 million U.S. children have ADHD; approximately two-thirds continue experiencing symptoms into adulthood (Sibley et al., Am J Psychiatry, 2022).
A 2024 randomized controlled trial in adolescents found measurable brain engagement from structured attention training, consistent with broader neuroplasticity research on attention network development.
Parents with children who struggle with focus deserve clear answers on whether any intervention is managing symptoms or building underlying skills, and the right to pursue both.
A new Phase 3 ADHD drug trial launched for teens on June 26, 2026. Here are the questions parents are actually asking.
Common questions
Is solriamfetol approved for teens with ADHD?
No. FOCUS-3 is a Phase 3 clinical trial, not an approved treatment. The first patient was dosed on June 26, 2026. Results require months to years of follow-up; FDA approval, if it comes, requires a successfully completed trial plus regulatory review. No ADHD indication is currently approved for solriamfetol in any age group.
Should I try attention training instead of ADHD medication for my teen?
That decision belongs to you and your child’s doctor. The research supports that attention is a trainable cognitive skill, and structured practice strengthens the brain regions involved in ADHD. Many families find that skills training and medication work well together: medication helps a teen function while skills are being built. The goal is to understand both tools, not to choose one to avoid the other. A screener is a starting point, not a diagnosis. If your child might need formal accommodations such as an IEP or 504 plan, or you suspect a vision, hearing, or medical cause, a professional evaluation is the route to those supports.
What does non-stimulant mean for ADHD treatment?
Non-stimulant ADHD medications work on dopamine and norepinephrine without the amphetamine mechanism of stimulants like Adderall or Ritalin. Solriamfetol blocks the reabsorption of both neurotransmitters and also acts on TAAR1 and 5-HT1A receptor systems. Non-stimulants generally have a lower misuse potential and no DEA Schedule II classification. Effects sometimes build more slowly than stimulants, and FOCUS-3 is the first trial testing solriamfetol specifically in adolescents with ADHD.
How do I know if a treatment is building my teen’s attention or only managing symptoms?
Ask your provider: when we taper or stop this treatment, does my teen’s ability to focus hold up, or do symptoms return to baseline right away? A skill-building approach changes the underlying neural capacity; symptom management holds the line while the treatment is active. Both have value, but they serve different goals. Parents who ask this question directly are in a better position to understand what they are committing to.
FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled multicenter trial. Approximately 468 adolescents with ADHD ages 12 to 17 will be enrolled and randomized 1:1:1 to receive one of two doses of solriamfetol or placebo over six weeks. The primary measure is change from baseline in the ADHD Rating Scale (ADHD-RS-5) total score at week 6.
Solriamfetol works as a dopamine and norepinephrine reuptake inhibitor, plus TAAR1 agonist and 5-HT1A agonist, a non-stimulant mechanism that distinguishes it from amphetamine-based first-line treatments. The CDC reported in 2024 that approximately 7 million U.S. children are diagnosed with ADHD, and research in the American Journal of Psychiatry found that approximately two-thirds or more of children with ADHD continue to experience symptoms into adulthood (Sibley et al., 2022). The estimated annual societal cost of adult ADHD in the United States exceeds $120 billion (Schein et al., J Manag Care Spec Pharm, 2022).
Currently approved non-stimulant options for adolescents with ADHD are limited to atomoxetine, extended-release guanfacine, clonidine, and viloxazine. Solriamfetol would add a distinct mechanism to that short list if FOCUS-3 succeeds and FDA review follows.
What the coverage gets wrong
Most reporting on ADHD drug trials frames new pharmaceutical entries as progress for struggling children, which is accurate as far as it goes. What that framing consistently skips is the parallel research base showing that attention is a trainable cognitive skill. A 2024 randomized controlled trial in adolescents with ADHD found measurable brain engagement from structured attention training. Meta-analytic reviews confirm that adaptive practice leverages neuroplasticity in the same prefrontal cortex regions targeted by ADHD medications. Medication and skills training serve different purposes, and parents deserve to understand both before any approach is chosen.
The Frame Coverage Keeps Missing
Every new ADHD drug trial gets reported as progress for children who struggle, and that framing is not wrong. It is incomplete. While the pharmaceutical industry funds six-week symptom trials, a parallel body of research has been building a different case: attention is a cognitive skill that responds to training, not only to chemistry.
A 2024 randomized controlled trial of 62 adolescents with ADHD tested a structured executive working memory training program and found clear evidence of target engagement with improvements on task-specific outcomes (ScienceDirect, 2024). Meta-analytic reviews confirm that adaptive cognitive training leverages neuroplasticity to strengthen the brain regions most affected in ADHD, including the prefrontal cortex. This is the same plasticity principle that brain-imaging research at Yale (Shaywitz) and Stanford (Temple) documented in children who struggled with reading: with the right kind of practice, the brain physically rewires. The same mechanism governs how attention networks develop.
The distinction that coverage consistently skips is the difference between symptom management and skill development. Solriamfetol, if it completes trials and reaches approval, would provide a pharmacological scaffold during the treatment window. Attention training, by contrast, aims to strengthen the underlying neural networks so the scaffold becomes less necessary over time. Both approaches have evidence behind them. What most parents are not given is a clear explanation of which goal any intervention is pursuing, or what the research shows about building attention skills alongside medication.
Key Takeaways:
1
New Trial Launches: Axsome Therapeutics dosed the first patient in FOCUS-3 on June 26, 2026, a non-stimulant ADHD trial enrolling 468 adolescents ages 12 to 17 over six weeks.
2
Attention Is Trainable: A 2024 RCT in adolescents with ADHD found measurable brain engagement from executive function training; neuroplasticity research confirms that attention networks strengthen with structured practice.
3
Two Different Goals: Symptom management and skill building are not the same thing. Parents deserve clear answers on which one any given intervention is pursuing.
The Questions Worth Putting to Your Child’s Doctor
If your child’s provider raises a new ADHD medication, a few questions belong on the table. First: is this medication intended to help your child function while building skills, or is it the primary plan? Second: what does the research show about what happens to attention when the medication is tapered or stopped? A treatment that builds underlying capacity answers that differently than one that manages symptoms in the moment.
The research on attention development points consistently toward factors parents do control: structured attention practice with progressive difficulty, regular physical movement (which increases dopamine and strengthens prefrontal cortex function), quality sleep, and intentional management of high-stimulation screen time. None of those require waiting for a trial to complete or a drug to be approved, and none carry the uncertainty about adolescent safety data that any Phase 3 trial, by definition, has not yet resolved.
The pharmaceutical-first framing for teen ADHD is not wrong. Medications help many adolescents function well enough to learn, and a non-stimulant option with a novel mechanism is genuinely worth watching. The slip happens when managing symptoms well enough to get through class gets treated as the same thing as building the attention skills that hold up when the medication is not there. Parents who understand both goals are better equipped to ask the right questions and push for both.
Every drug trial announcement that reaches a parent carries an implicit message: this is where the answer lives. The true villain in teen ADHD coverage is not any drug or company. It is the framing that hands parents a pipeline update and sends them home without the training side of the story. Your teen’s attention is not a neurochemical state waiting for the right pill. It is a system of neural networks that grows stronger with the right kind of challenge. If you are ready to explore what building attention looks like in practice, the All Access program is where to start.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
